AG1343 HIV protease inhibitor data

The La Jolla, Calif., company presented results of two U.K. Phase I trials at the Second National Conference on Human Retroviruses and Related Infections in Washington, showing no adverse effects in normal volunteers.

Doses tested were 100, 200, 400 and 800 mg orally given to two groups of six each. ...